Delgocitinib

DRUG8 trials

Sponsors

LEO Pharma, Icahn School of Medicine at Mount Sinai

Conditions

Atopic DermatitisCentral Centrifugal Cicatricial AlopeciaChronic Hand EczemaLichen PlanopilarisLichen Sclerosus

Phase 1

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

CompletedNCT03826901

LEO PharmaAtopic Dermatitis

Start: 2019-02-20End: 2021-10-29Updated: 2025-02-24

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

CompletedNCT05486117

LEO PharmaChronic Hand Eczema

Start: 2022-09-06End: 2022-11-22Updated: 2025-04-04

Phase 2

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Not yet recruitingNCT07487948

Icahn School of Medicine at Mount SinaiCentral Centrifugal Cicatricial Alopecia, Lichen Planopilaris

Start: 2026-05-04End: 2027-12-31Target: 30Updated: 2026-03-23

Phase 3

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

CompletedNCT04949841

LEO PharmaChronic Hand Eczema

Start: 2021-08-23End: 2023-09-18Updated: 2025-04-08

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

CompletedNCT05259722

LEO PharmaChronic Hand Eczema

Start: 2022-06-15End: 2023-12-05Updated: 2025-05-09

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

CompletedNCT05355818

LEO PharmaChronic Hand Eczema

Start: 2022-07-14End: 2024-12-17Updated: 2025-07-29

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

CompletedNCT06004050

LEO PharmaChronic Hand Eczema

Start: 2023-09-05End: 2025-09-12Updated: 2025-09-25

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

Not yet recruitingNCT07335588

LEO PharmaLichen Sclerosus

Start: 2026-05-06End: 2028-12-29Target: 652Updated: 2026-02-20

Related Papers

Editorial: Exploring innovative therapies for rare inflammatory skin diseases

Frontiers in Medicine2026-03-19

Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema

Journal of the European Academy of Dermatology and Venereology2025-06-179 citations

Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.

2025-04-169 citations

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.

2025-03-1110 citations

655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial

British Journal of Dermatology2024-08-015 citations